Humanized mice carrying a pathogenic GRN deletion as a pre-clinical platform for targeted gene therapies in frontotemporal dementia
Neurobiology of Disease · 2026
DOI: 10.1016/j.nbd.2026.107419 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurobiology of Disease, 2026. Verfasst von Benjamin E Life und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 0B3, Canada; BC Chi…. Hauptthemen laut MEDLINE: Progranulins, Frontotemporal Dementia, Genetic Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Weston Brain Institute, Canadian Institutes of Health Research, BC Children's Hospital.
Themen: Demenz
Abstract (Originalsprache)
Frontotemporal dementia (FTD) is an early onset dementia characterized by neuropathology and changes to patient behaviour. Haploinsufficiency of the gene progranulin (GRN) is a major cause of FTD, for which there are no effective therapies. Corrective gene therapies that restore GRN expression are of clinical interest, but current in vivo systems have limitations. We developed a novel strain of mice expressing a human GRN transgene bearing a four base pair deletion in exon 5 (GRNc.388_391delCAGT) that causes FTD. Characterization of mice expressing the mutant transgene (GRNmEx5) indicates that GRNmEx5 is expressed at low levels and retains partial function. The GRNmEx5 protein partially rescues progranulin nullizygous-associated neuropathology and transcriptomic dysfunction. Following characterization, we sought to determine if mice expressing GRNmEx5 in the absence of mouse progranulin (Grn-/-; GRNmEx5 mice) could enable pre-clinical gene therapy development. Using CRISPR/Cas9 with lipid nanoparticle delivery, we achieved 8.5% correction of GRNc.388_391delCAGT in target cells in Grn-/-; GRNmEx5 mice, demonstrating both effective in vivo homology-directed repair and the utility of Grn-/-; GRNmEx5 mice for developing novel progranulin-associated FTD therapies. The Grn-/-; GRNmEx5 model provides insight into progranulin biology, increases our understanding of a pathogenic variant that causes FTD, and facilitates the development of GRN gene therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 0B3, Canada; BC Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada.
- BC Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada; Department of Statistics, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
- BC Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada.
- Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 0B3, Canada; BC Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada; De…
- Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 0B3, Canada; BC Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada; Di…
Förderung
- Weston Brain Institute
- Canadian Institutes of Health Research
- BC Children's Hospital
Zitieren
APA
Life, B. E., Kazemian, P., Petkau, T. L., de Moura Gomes, A., Thomson, S. B., Shen, N., Myung, J., Jayousi, F., Lengyell, T. C., Lange, P. F., Simpson, E. M., Korthauer, K., & Leavitt, B. R. (2026). Humanized mice carrying a pathogenic GRN deletion as a pre-clinical platform for targeted gene therapies in frontotemporal dementia. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2026.107419
Vancouver
Life BE, Kazemian P, Petkau TL, de Moura Gomes A, Thomson SB, Shen N, et al. Humanized mice carrying a pathogenic GRN deletion as a pre-clinical platform for targeted gene therapies in frontotemporal dementia. Neurobiology of Disease. 2026. doi:10.1016/j.nbd.2026.107419
BibTeX
@article{Life2026,
author = {Life, Benjamin E and Kazemian, Pardis and Petkau, Terri L and de Moura Gomes, Alissandra and Thomson, Sarah B and Shen, Ning and Myung, Junia and Jayousi, Farah and Lengyell, Tess C and Lange, Philipp F and Simpson, Elizabeth M and Korthauer, Keegan and Leavitt, Blair R},
title = {Humanized mice carrying a pathogenic GRN deletion as a pre-clinical platform for targeted gene therapies in frontotemporal dementia},
journal = {Neurobiology of Disease},
year = {2026},
doi = {10.1016/j.nbd.2026.107419}
}
EUVIMED